sulbactam has been researched along with Community Acquired Infection in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.45) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 12 (41.38) | 24.3611 |
| 2020's | 6 (20.69) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CH; Chen, CM; Chen, WC; Fang, WF; Fu, PK; Huang, CT; Ku, SC; Kuo, LK; Lai, CC; Tu, CY; Wang, YT | 1 |
| Ikawa, K; Ishihara, N; Morikawa, N; Naora, K; Onita, T; Tamaki, H; Yano, T | 1 |
| Fang, X; Huang, F; Wang, J; Yu, J | 1 |
| Chen, CH; Chen, CM; Chen, WC; Cheng, WC; Fang, WF; Fu, PK; Ku, SC; Kuo, LK; Lai, CC; Tu, CY; Wang, YT | 1 |
| Chua, HH; Tonnii, S | 1 |
| Hamao, N; Hirai, T; Ito, I; Kadowaki, S; Konishi, S; Matsumoto, H; Oi, I; Shirata, M; Tanabe, N; Tsukino, M; Yasutomo, Y | 1 |
| Djubailo, AV; Fatenkov, OV; Kuzmina, TM; Rubanenko, OA; Svetlova, GN | 1 |
| Fujita, J; Higa, F; Hiramatsu, K; Kadota, J; Kohno, S; Tateyama, M; Tokimatsu, I; Yamamoto, Y; Yanagihara, K | 1 |
| Chen, CW; Ma, CJ; Ming, CC; Shan, YS; Wang, JY; Yeh, YS | 1 |
| Drewelow, B; Frimmel, S; Klammt, S; Loebermann, M; Majcher-Peszynska, J; Mundkowski, RG; Reisinger, EC; Welte, T | 1 |
| Bandettini, R; Buffa, P; Castagnola, E; Caviglia, I; Ciucci, A; Ginocchio, F; Guida, E; Haupt, R; Loy, A; Masa, DL; Mattioli, G; Perotti, M; Pini Prato, A | 1 |
| Marshall, S; Muto, C; Shoji, S; Soto, E; Tomono, Y | 1 |
| Itamura, R; Kadota, J; Kohno, S; Mikamo, H; Niki, Y; Tateda, K | 1 |
| Çilli, A; Karaboğa, B | 1 |
| Badal, RE; Cao, B; Chen, S; Chu, Y; Duan, Q; Feng, X; Gui, B; Hu, B; Hu, Z; Huang, W; Kong, H; Liao, K; Luo, Y; Ni, Y; Shao, H; Su, J; Sun, Z; Wang, Y; Wu, A; Xu, Y; Yang, Q; Yu, Y; Zhang, H; Zhang, S | 1 |
| Badía, M; Cassini, E; Córdova, E; Gómez, N; López Moral, L; Morganti, L; Rodríguez, C | 1 |
| Higashiyama, Y; Imamura, Y; Izumikawa, K; Kakeya, H; Kohno, S; Kurihara, S; Nakamura, S; Seki, M; Tashiro, T; Yamamoto, Y; Yanagihara, K | 1 |
| Belet, N; Çiftçi, E; Doğru, Ü; Ince, E; Özdemir, H; Tapısız, A | 1 |
| Ansaloni, L; Catena, F; Coccolini, F; Di Saverio, S; Ercolani, G; Gazzotti, F; Lazzareschi, D; Pinna, AD | 1 |
| Absi, R; Arenoso, H; Bantar, C; Bustos, JL; Curcio, D; Franco, D; Izaguirre, M; Jasovich, A; Larrateguy, L; Mastruzzo, M; Mobilia, L; Morera, G; Oliva, ME; Prieto, S; Soutric, J; Vesco, E | 1 |
| Asaoka, N; Fujita, K; Honda, N; Kurihara, T; Nakamura, J; Ohba, H; Okimoto, N | 1 |
| Marinella, MA | 1 |
| Arbo, A; Lovera, D | 1 |
| Fukuda, Y; Higashiyama, Y; Hirakata, Y; Izumikawa, K; Kohno, S; Miyazaki, Y; Mizuta, Y; Seki, M; Tomono, K; Tsukamoto, K; Yanagihara, K | 1 |
| Barcelona, L; Marín, M; Stamboulian, D | 1 |
| Cepparulo, M; Ciliberti, G; Dal Farra, F; Ghelfi, R; Guelfi, R; Mancuso, I; Paris, R; Pirica, P; Pirina, P; Serra, G; Todisco, T | 1 |
| Perri, M; Williams, D; Zervos, MJ | 1 |
| Arenoso, HJ; Bantar, C; Blanco, M; Fernandez Canigia, L; Jasovich, A; Montoto, M; Nicola, F; Smayevsky, J; Soutric, J | 2 |
1 review(s) available for sulbactam and Community Acquired Infection
| Article | Year |
|---|---|
[Betalactam antibiotics combined with bectalactamases inhibitors. Amoxicillin-sulbactam].
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Pneumonia, Bacterial; Pulmonary Disease, Chronic Obstructive; Sulbactam | 2008 |
12 trial(s) available for sulbactam and Community Acquired Infection
| Article | Year |
|---|---|
Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Ceftriaxone; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Japan; Macrolides; Male; Middle Aged; Pneumonia; Prospective Studies; Risk Factors; Sulbactam | 2020 |
Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Injections, Intravenous; Japan; Male; Middle Aged; Pneumonia, Bacterial; Recurrence; Sulbactam; Treatment Outcome | 2013 |
Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-acquired complicated intra-abdominal infections.
Topics: Adult; Aged; Aged, 80 and over; Ampicillin; Analysis of Variance; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Intraabdominal Infections; Logistic Models; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Risk Factors; Sulbactam; Taiwan; Treatment Outcome; Young Adult | 2013 |
Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Community-Acquired Infections; Computer Simulation; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Female; Humans; Infusions, Intravenous; Japan; Kidney; Kidney Diseases; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Pneumonia, Bacterial; Sulbactam | 2014 |
Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study.
Topics: Adolescent; Adult; Aged; Ampicillin; Anti-Bacterial Agents; Bacteria; Community-Acquired Infections; Female; Humans; Japan; Male; Middle Aged; Pneumonia, Bacterial; Sputum; Sulbactam; Treatment Outcome; Young Adult | 2015 |
A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia.
Topics: Aged; Aged, 80 and over; Ampicillin; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperacillin; Pneumonia, Bacterial; Prospective Studies; Radiography; Sulbactam | 2009 |
A prospective, multi centre, randomized clinical study to compare the efficacy and safety of Ertapenem 3 days versus Ampicillin-Sulbactam 3 days in the treatment of localized community acquired intra-abdominal infection. (T.E.A. Study: Three days Ertapene
Topics: Abdomen; Adult; Ampicillin; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Clinical Protocols; Community-Acquired Infections; Drug Therapy, Combination; Ertapenem; Humans; Peritonitis; Sulbactam | 2011 |
Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community-acquired pneumonia: a clinical trial based on a pharmacodynamic model.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Community-Acquired Infections; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Sulbactam; Time Factors; Treatment Outcome | 2002 |
Treatment of childhood complicated community-acquired pneumonia with amoxicillin/sulbactam.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Cefuroxime; Child; Child, Preschool; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Inpatients; Male; Pneumonia; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Sulbactam; Treatment Outcome | 2005 |
Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia.
Topics: Age Factors; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Cilastatin; Community-Acquired Infections; Drug Combinations; Female; Humans; Imipenem; Male; Pneumonia, Bacterial; Prospective Studies; Protease Inhibitors; Severity of Illness Index; Sulbactam; Treatment Outcome | 2006 |
An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ampicillin; Anti-Bacterial Agents; Azithromycin; Community-Acquired Infections; Drug Combinations; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Sulbactam | 2008 |
Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Ampicillin; Bacteria; Bacterial Infections; Cefamandole; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia; Prospective Studies; Sputum; Sulbactam | 1994 |
16 other study(ies) available for sulbactam and Community Acquired Infection
| Article | Year |
|---|---|
Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefoperazone; Cohort Studies; Community-Acquired Infections; Female; Frail Elderly; Healthcare-Associated Pneumonia; Humans; Male; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated; Retrospective Studies; Sulbactam; Treatment Outcome | 2022 |
Pharmacodynamic Evaluation of Ampicillin-sulbactam in Pediatric Patients Using Plasma and Urine Data.
Topics: Adolescent; Adult; Aged; Ampicillin; Anti-Bacterial Agents; Child; Child, Preschool; Community-Acquired Infections; Humans; Microbial Sensitivity Tests; Middle Aged; Sulbactam; Young Adult | 2022 |
Investigation and Analysis of Infection among Inpatients in a Tertiary Hospital in Shanghai.
Topics: Adult; Anti-Bacterial Agents; Cefoperazone; China; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Humans; Inpatients; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Retrospective Studies; Sulbactam; Tertiary Care Centers | 2022 |
The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Cefoperazone; Community-Acquired Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Retrospective Studies; Sulbactam; Treatment Outcome | 2023 |
Case series: Fulminant community-acquired Acinetobacter pneumonia.
Topics: Acinetobacter; Acinetobacter Infections; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Fatal Outcome; Humans; Male; Middle Aged; Sulbactam | 2020 |
[Community acquired bacterial pneumonia and comorbidity in elderly patients].
Topics: Aged; Ampicillin; Anti-Bacterial Agents; Community-Acquired Infections; Comorbidity; Female; Heart Failure; Humans; Male; Pneumonia, Bacterial; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Sulbactam | 2017 |
Ampicillin/sulbactam in elderly patients with community-acquired pneumonia.
Topics: Age Factors; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Community-Acquired Infections; Female; Humans; Injections, Intravenous; Male; Microbial Sensitivity Tests; Plasma; Pneumonia, Pneumococcal; Prospective Studies; Streptococcus pneumoniae; Sulbactam; Time Factors; Treatment Outcome | 2014 |
Susceptibility to antibiotics of aerobic bacteria isolated from community acquired secondary peritonitis in children: therapeutic guidelines might not always fit with and everyday experience.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Child; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Gentamicins; Hospitals, Pediatric; Humans; Italy; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Sulbactam; Thienamycins | 2013 |
[Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia].
Topics: Adult; Aged; Ampicillin; Anti-Bacterial Agents; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Length of Stay; Macrolides; Male; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Sulbactam | 2015 |
Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefoxitin; China; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Gene Expression; Humans; Imipenem; Intraabdominal Infections; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2016 |
[Antimicrobial susceptibility of Gram-negative bacilli of community acquired intra-abdominal infections in a hospital at Buenos Aires, Argentina].
Topics: Abdomen; Adolescent; Adult; Aged; Ampicillin; Anti-Bacterial Agents; Argentina; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Sulbactam; Young Adult | 2016 |
Ampicillin/sulbactam for children hospitalized with community-acquired pneumonia.
Topics: Adolescent; Ampicillin; Child; Child, Preschool; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Infant; Male; Multivariate Analysis; Odds Ratio; Pneumonia, Bacterial; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Sulbactam; Treatment Failure; Turkey | 2011 |
Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly.
Topics: Aged; Aged, 80 and over; Ampicillin; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Male; Pneumonia, Bacterial; Sulbactam | 2003 |
Community-acquired pneumonia due to Pasteurella multocida.
Topics: Aged; Ampicillin; Animals; Anti-Bacterial Agents; Cats; Community-Acquired Infections; Dogs; Humans; Male; Pasteurella Infections; Pasteurella multocida; Pneumonia, Bacterial; Sulbactam; Zoonoses | 2004 |
A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections.
Topics: Administration, Oral; Adult; Amoxicillin; Anti-Bacterial Agents; Community-Acquired Infections; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Haemophilus Infections; Haemophilus influenzae; Humans; Male; Models, Biological; Moraxella catarrhalis; Neisseriaceae Infections; Penicillins; Pneumococcal Infections; Respiratory Tract Infections; Serum Bactericidal Test; Streptococcus pneumoniae; Sulbactam | 2000 |
Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms.
Topics: Administration, Oral; Adult; Amoxicillin; Community-Acquired Infections; Drug Therapy, Combination; Female; Haemophilus influenzae; Humans; Male; Microbial Sensitivity Tests; Moraxella catarrhalis; Penicillin Resistance; Pneumonia, Bacterial; Serum Bactericidal Test; Streptococcus pneumoniae; Sulbactam | 2001 |